Aspira Women's Health Inc (AWHL) USD0.001

Sell:$0.53Buy:$0.53$0.01 (1.87%)

Prices delayed by at least 15 minutes
Sell:$0.53
Buy:$0.53
Change:$0.01 (1.87%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.53
Buy:$0.53
Change:$0.01 (1.87%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.

Key people

Michael Buhle
Chief Executive Officer
Brian Hungerford
Chief Financial Officer, Principal Accounting Officer
Winfred Parnell
Independent Director
Jane Pine Wood
Director
Ellen Beausang
Independent Director
Jeffrey Cohen
Independent Director
John Fraser
Independent Director
Click to see more

Key facts

  • EPIC
    AWHL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US04537Y2081
  • Market cap
    $23.95m
  • Employees
    66
  • Shares in issue
    42.21m
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.